Rapid and sensitive HPLC-MS/MS method for pharmacokinetic assessment of ribavirin in healthy Chinese

Biomedical Chromatography

Volumn 22, Issue 12, 2008, Pages 1409-1415

  Zhou, Zhi Ling ^a   Yu, Xi Yong ^a   Yang, Min ^a   Peng, Huai Yan ^b   Chen, Tei Feng ^a   Lin, Qiu Xiong ^a   Shan, Zhi Xin ^a   Liu, Xiao Ying ^a   Deng, Chun Yu ^a   Zhu, Ping ^a   Huang, Xiao Zhong ^a   Lin, Shu Guang ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

HPLC MS MS; Pharmacokinetics; Quantitative assay; Ribavirin

Indexed keywords

AMIDES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; VIRUSES;

ACETATE BUFFERS; AMMONIUM ACETATE; ASSAY METHODS; CHROMATOGRAPHIC SEPARATIONS; CONSTANT FLOW RATES; HPLC-MS-MS; HUMAN PLASMAS; MAXIMUM CONCENTRATIONS; QUANTITATIVE ASSAY; RIBAVIRIN;

PHARMACOKINETICS;

ACETONITRILE; ACICLOVIR; AMMONIUM ACETATE; FORMIC ACID; RIBAVIRIN; WATER; ANTIVIRUS AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALIBRATION; CHINESE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; ASIAN; BLOOD; CHINA; METHODOLOGY; ORAL DRUG ADMINISTRATION; REPRODUCIBILITY;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; REPRODUCIBILITY OF RESULTS; RIBAVIRIN; TANDEM MASS SPECTROMETRY;

EID: 59649129296     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1074     Document Type: Article

References (23)

1. Arase Y, Ikeda K, Tsubota A, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kobayashi M and Kumada H. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 2005; 48: 138-144.
2. D'Avolio A, Ibanez A, Sciandra M, Siccardi M, de Requena DG, Bonora S and Di Perri G. Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. Journal of Chromatography B, Analytical Technology in the Biomedical and Life Sciences 2006; 835: 127-130.
3. Dixit NM and Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cellular and Molecular Life Sciences 2006; 63: 832-842.
4. Glue P. The clinical pharmacology of ribavirin. Seminars in Liver Disease 1999; 19(suppl. 1): 17-24.
5. Glue P, Schenker S, Gupta S, Clement RP, Zambas D and Salfi M. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. British Journal of Clinical Pharmacology 2000; 49: 417-421.
6. Granich GG, Krogstad DJ, Connor JD, Desrochers KL and Sherwood C. High-performance liquid chromatography (HPLC) assay for ribavirin and comparison of the HPLC assay with radioimmunoassay. Antimicrobial Agents and Chemotherapy 1989; 33: 311-315.
7. Inoue Y, Homma M, Matsuzaki Y, Shibata M, Matsumura T, Ito T, Mitamura K, Tanaka N and Kohda Y. Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood. Antimicrobial Agents and Chemotherapy 2004; 48: 3813-3816.
8. Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, Lypnyj D, Flannery B, Walters K and Dusheiko GM. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998; 46: 563-570.
9. Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G and Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrobial Agents and Chemotherapy 2003; 47: 124-129.
10. Li W, Luo S, Li S, Athill L, Wu A, Ray T, Zhou W, Ke J, Smith HT and Tse FL. Simultaneous determination of ribavirin and ribavirin base in monkey plasma by high performance liquid chromatography with tandem mass spectrometry. Journal of Chromatography B, Analytical Technology in the Biomedical and Life Sciences 2007; 846: 57-68.
11. Lin CC, Yeh LT and Lau JY. Specific, sensitive and accurate liquid chromatographic-tandem mass spectrometric method for the measurement of ribavirin in rat and monkey plasma. Journal of Chromatography B, Analytical Technology in the Biomedical and Life Sciences 2002; 779: 241-248.
12. Lindahl K, Stahle L, Bruchfeld A and Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41: 275-279.
13. Liu Y, Xu C, Yan R, Lim C, Yeh LT and Lin CC. Sensitive and specific LC-MS/MS method for the simultaneous measurements of viramidine and ribavirin in human plasma. Journal of Chromatography B, Analytical Technology in the Biomedical and Life Sciences 2006; 832: 17-23.
14. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C and Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
15. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD and Everhart JE. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-1023; discussion 1947.
16. Shou WZ, Bu HZ, Addison T, Jiang X and Naidong W. Development and validation of a liquid chromatography/tandem mass spectrometry (LC/MS/ MS) method for the determination of ribavirin in human plasma and serum. Journal of Pharmaceutical and Biomedical Analysis 2002; 29: 83-94.
17. State Food and Drug Administration of China. SFDA notification about the revised specification of ribavirin particles http://www.pharmnet.com.cn/ zcfg/2006/03/21/101503.html, 2006
18. Svensson JO, Bruchfeld A, Schvarcz R and Stahle L. Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chromatography. Therapeutic Drug Monitoring 2000; 22: 215-218.
19. Thomas DL. Options for treatment of hepatitis C in HIV-infected persons. Journal of Hepatology 2006; 44: S40-43.
20. Vo NV, Young KC and Lai MM. Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry 2003; 42: 10462-10471.
21. Yeh LT, Nguyen M and Lin CC. A sensitive and specific method for the determination of total ribavirin in human red blood cells by liquid chromatography-tandem mass spectrometry. Journal of Chromatographic Science 2003; 41: 255-260.
22. Yeh LT, Nguyen M, Lourenco D and Lin CC. A sensitive and specific method for the determination of total ribavirin in monkey liver by high-performance liquid chromatography with tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2005; 38: 34-40.
23. Yeh LT, Nguyen M, Dadgostari S, Bu W and Lin CC. LC-MS/MS method for simultaneous determination of viramidine and ribavirin levels in monkey red blood cells. Journal of Pharmaceutical and Biomedical Analysis 2007; 43: 1057-1064.